UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000038758
Receipt number R000044180
Scientific Title Longitudinal MRI study Identifying the Neural Substrates of Remission/Recovery in Mood Disorders
Date of disclosure of the study information 2019/12/02
Last modified on 2019/12/18 15:09:55

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Longitudinal MRI study Identifying the Neural Substrates of Remission/Recovery in Mood Disorders

Acronym

L/R Study

Scientific Title

Longitudinal MRI study Identifying the Neural Substrates of Remission/Recovery in Mood Disorders

Scientific Title:Acronym

L/R Study

Region

Japan


Condition

Condition

Major depressive disorder

Classification by specialty

Psychiatry

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

The aims of this study are: (1) to investigate the underlying biological mechanisms of representative treatments for depressive state (i.e., pharmacological treatment, cognitive behavioral therapy (CBT), repetitive transcranial magnetic stimulation (rTMS), and electroconvulsive therapy (ECT)); (2) to investigate changes in neural circuits common or specific to each treatment; and (3) to elucidate biological predictors for each treatment.

Basic objectives2

Others

Basic objectives -Others

We examine brain functional or structural alterations with clinical improvements in four therapeutic interventions and identify the neural networks specific to treatment response in each treatment. By applying a machine learning technique to individual data, including MRI data, data on participants' backgrounds, and clinical data, we aim to develop a novel model that accurately predicts treatment response and course trajectory in mood disorders

Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

brain structural and functional data based on 3D-T1 imaging (sMRI) and resting-state functional MRI (rs-fMRI)

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

85 years-old >=

Gender

Male and Female

Key inclusion criteria

Inclusion criteria were as follows: those who 1) met the criteria for a depression/major depressive disorder or persistent depressive disorder under DSM-5 diagnostic guidelines; 2) were scheduled to undergo electroconvulsive therapy, cognitive behavioral therapy, psychopharmaco therapy, or repetitive transcranial magnetic stimulation; 3) can understand the purpose and content of this study and express written consent to participate in this study based on their will; and 4) scored more than 8 points on the Hamilton Rating Scale for Depression.

Key exclusion criteria

Exclusion criteria were as follows: those who 1) had a history of drug or alcohol misuse within two years; 2) demonstrate manic episodes; 3) currently have suicidal ideation or have attempted suicide in the past; 4) have antisocial personality disorder; 5) will become unable to continue visiting the hospital (e.g., moving away); 6) have reported an unstable medical condition or history of significant head trauma; 7) are unable to undergo MRI scans due to metal in the body; 8) have claustrophobia; 9) are judged otherwise unsuitable for this study.

Target sample size

500


Research contact person

Name of lead principal investigator

1st name Masaru
Middle name
Last name Mimura,

Organization

Keio University, School of Medicine

Division name

Psychiatry

Zip code

160-0016

Address

35 Sinanomachi Shinjyuku Tokyo

TEL

03-5379-0187

Email

mimura@a7.keio.jp


Public contact

Name of contact person

1st name Jinichi
Middle name
Last name Hirano

Organization

Keio University, School of Medicine

Division name

Psychiatry

Zip code

160-0016

Address

35 Sinanomachi Shinjyuku Tokyo

TEL

03-5379-0187

Homepage URL


Email

hjinichi@gmail.com


Sponsor or person

Institute

Keio University

Institute

Department

Personal name



Funding Source

Organization

Japan Agency for Medical Research and Development (AMED)

Organization

Division

Category of Funding Organization

Japanese Governmental office

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Research Ethics Committee of Keio university, school of medicine

Address

35 Sinanomachi Shinjyuku Tokyo

Tel

+81.3.3353.1211(x62014)

Email

med-rinri-jimu@adst.keio.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2019 Year 12 Month 02 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Enrolling by invitation

Date of protocol fixation

2019 Year 11 Month 25 Day

Date of IRB

2019 Year 11 Month 25 Day

Anticipated trial start date

2019 Year 12 Month 02 Day

Last follow-up date

2024 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

This study is a multicenter (Keio University, Kyoto University, National center of Neurology and psychiatry), open study based on usual care, and the observation period is about 7-10 months in principle. Patients who will receive any one of four treatments (pharmacotherapy, cognitive behavioral therapy, electroconvulsive therapy, and repetitive transcranial magnetic stimulation) are recruited as potential subjects, and a healthy group is also recruited.
MRI scans and clinical evaluations are conducted three times: once each within two-week periods before and after treatment, and once six months after treatment.


Management information

Registered date

2019 Year 12 Month 02 Day

Last modified on

2019 Year 12 Month 18 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000044180


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name